X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (714) 714
animals (569) 569
benzodioxoles - pharmacology (510) 510
humans (425) 425
male (412) 412
pharmacology & pharmacy (306) 306
mice (288) 288
benzodioxoles - therapeutic use (275) 275
rats (245) 245
piperidines - pharmacology (244) 244
piperine (184) 184
female (180) 180
alkaloids - pharmacology (161) 161
polyunsaturated alkamides - pharmacology (149) 149
benzodioxoles - administration & dosage (122) 122
benzodioxoles - chemistry (121) 121
article (118) 118
neurosciences (118) 118
dose-response relationship, drug (114) 114
analysis (109) 109
cell line, tumor (104) 104
piperidines - therapeutic use (100) 100
disease models, animal (97) 97
in-vitro (97) 97
biochemistry & molecular biology (89) 89
rats, wistar (88) 88
oxidative stress (86) 86
cancer (85) 85
rats, sprague-dawley (85) 85
mice, inbred c57bl (81) 81
chemistry, medicinal (80) 80
research (80) 80
inhibition (78) 78
activation (76) 76
apoptosis (75) 75
cystic fibrosis - drug therapy (75) 75
expression (74) 74
benzodioxoles (73) 73
oncology (70) 70
adult (68) 68
alkaloids - therapeutic use (67) 67
cystic fibrosis transmembrane conductance regulator - genetics (67) 67
cell proliferation - drug effects (66) 66
polyunsaturated alkamides - therapeutic use (65) 65
proteins (65) 65
signal transduction - drug effects (65) 65
monoacylglycerol lipases - antagonists & inhibitors (64) 64
mutation (63) 63
cell biology (61) 61
health aspects (61) 61
quinolones - therapeutic use (61) 61
aminophenols - therapeutic use (60) 60
aminopyridines - therapeutic use (60) 60
cystic fibrosis (60) 60
metabolism (60) 60
apoptosis - drug effects (59) 59
cystic fibrosis - genetics (59) 59
care and treatment (58) 58
black pepper (57) 57
research article (57) 57
piperidines - administration & dosage (56) 56
rodents (55) 55
inflammation (54) 54
cells (52) 52
pharmacology (52) 52
alkaloids (51) 51
quinazolines - pharmacology (51) 51
antineoplastic agents - pharmacology (50) 50
enzyme inhibitors - pharmacology (49) 49
middle aged (49) 49
piperidines - chemistry (49) 49
toxicology (49) 49
benzodioxoles - adverse effects (48) 48
brain (48) 48
cell line (48) 48
medicine (48) 48
alkaloids - chemistry (47) 47
enzymes (45) 45
multidisciplinary sciences (45) 45
curcumin (44) 44
lipase (44) 44
pharmacology/toxicology (44) 44
src-family kinases - antagonists & inhibitors (44) 44
cells, cultured (43) 43
alkaloids - administration & dosage (42) 42
bioavailability (42) 42
cell survival - drug effects (42) 42
drug combinations (42) 42
lipids (42) 42
phosphorylation (42) 42
psychiatry (42) 42
antioxidants (41) 41
physiological aspects (41) 41
polyunsaturated alkamides (41) 41
antioxidants - pharmacology (40) 40
drug therapy (40) 40
drugs (40) 40
in-vivo (40) 40
oxidative stress - drug effects (40) 40
pharmacokinetics (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (855) 855
German (6) 6
French (4) 4
Russian (4) 4
Japanese (3) 3
Chinese (2) 2
Hungarian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9773, pp. 1276 - 1287
Summary Osteoporosis is a common disease characterised by a systemic impairment of bone mass and microarchitecture that results in fragility fractures. With an... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | SCLEROSTIN ANTIBODY | BONE-MINERAL DENSITY | CALCIUM-SENSING RECEPTOR | HUMAN OSTEOBLASTIC CELLS | OSTEOPROTEGERIN LIGAND | CATHEPSIN-K INHIBITOR | STRONTIUM RANELATE | VERTEBRAL FRACTURE | HEALTHY POSTMENOPAUSAL WOMEN | FRACTURE RISK | Wnt Proteins - drug effects | Vitamin D Deficiency - complications | Calcium - metabolism | Bone Morphogenetic Proteins - immunology | Humans | Middle Aged | Osteoporosis - diagnosis | Osteoporosis, Postmenopausal - metabolism | Antibodies, Monoclonal - therapeutic use | Osteoporosis - drug therapy | Wnt Proteins - metabolism | Biphenyl Compounds - therapeutic use | Osteoporosis - etiology | Bone Remodeling - drug effects | Antibodies, Monoclonal, Humanized | Osteoporosis - metabolism | Vitamin D Deficiency - therapy | Aged, 80 and over | Bone Resorption - metabolism | Diphosphonates - therapeutic use | Female | Benzodioxoles - therapeutic use | RANK Ligand - therapeutic use | Anabolic Agents - therapeutic use | Osteoporosis - prevention & control | Risk Assessment | Osteoporotic Fractures - prevention & control | Risk Factors | Bone Resorption - drug therapy | Bone Density Conservation Agents - therapeutic use | Denosumab | Absorptiometry, Photon | Genetic Markers - immunology | Osteoclasts - metabolism | Osteoporosis, Postmenopausal - drug therapy | Randomized Controlled Trials as Topic | Bone Density - drug effects | Quinazolines - therapeutic use | Aged | Osteoblasts - metabolism | Intercellular Signaling Peptides and Proteins - immunology | Osteoporosis | Complications and side effects | Care and treatment | Diagnosis | Bones | Vitamin D | Womens health | Metabolic disorders | Cathepsin K | Cytokines | Proteinase | Socio-economic aspects | SOST protein | Osteoblasts | Post-menopause | Bone resorption | NF- Kappa B protein | Bone mass | Fractures | Reviews | Aging | Monoclonal antibodies | Osteoclasts | Dkk1 protein | Osteogenesis | Communication
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1612 - 1620
This preclinical, phase 2 report shows that VX-445, a CFTR potentiator when administered with tezacaftor and ivacaftor, improved lung function and reduced... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | TEZACAFTOR-IVACAFTOR | CFTR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - administration & dosage | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Chlorides - metabolism | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - pharmacology | Pyridines - therapeutic use | Pyridines - administration & dosage | Double-Blind Method | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Pyrazoles - administration & dosage | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Pyridines - pharmacology | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Dosage and administration | Drug therapy | Statistical analysis | Writers | Epithelial cells | Chloride transport | Recovery of function | Patients | Design | Proteins | Genotype & phenotype | Chloride | Collaboration | Conductance | Full text | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Pharmaceuticals
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2018, Volume 379, Issue 17, pp. 1599 - 1611
This companion article to the VX-445 report shows that VX-659, a new CFTR potentiator, when administered with tezacaftor and ivacaftor improved lung function,... 
G551D MUTATION | MEDICINE, GENERAL & INTERNAL | IN-VITRO | CFTR POTENTIATOR | TEZACAFTOR-IVACAFTOR | Pyrazoles - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Pyrrolidines - adverse effects | Chloride Channel Agonists - therapeutic use | Male | Aminophenols - therapeutic use | Chloride Channel Agonists - adverse effects | Aminophenols - adverse effects | Pyrrolidines - pharmacology | Pyrrolidines - therapeutic use | Sweat - chemistry | Young Adult | Quinolones - adverse effects | Quinolones - therapeutic use | Adult | Benzodioxoles - adverse effects | Female | Benzodioxoles - therapeutic use | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Double-Blind Method | Cells, Cultured | Genotype | Cystic Fibrosis Transmembrane Conductance Regulator - metabolism | Chlorides - analysis | Indoles - adverse effects | Cystic Fibrosis - genetics | Adolescent | Alleles | Cystic Fibrosis Transmembrane Conductance Regulator - genetics | Indoles - therapeutic use | Mutation | Cystic Fibrosis - drug therapy | Drug Combinations | Cystic fibrosis | Ivacaftor | Genetic aspects | Dosage and administration | Drug therapy | Epithelial cells | Chloride transport | Clinical trials | Recovery of function | Patients | Proteins | Genotype & phenotype | Conductance | Full text | Cystic fibrosis transmembrane conductance regulator | Protein transport | Sweat | Binding sites | Genotypes
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 21, pp. 2013 - 2023
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2017, Volume 377, Issue 21, pp. 2024 - 2035
Journal Article
The Oncologist, ISSN 1083-7159, 05/2011, Volume 16, Issue 5, pp. 566 - 578
Src is believed to play an important role in cancer, and several agents targeting Src are in clinical development. Design. We reviewed Src structure and... 
Dasatinib | Solid tumor | Biologic | Bosutinib | Src inhibitors | Saracatinib | SARACATINIB AZD0530 | ACTIVATION | PROTEIN-TYROSINE KINASES | PHASE-II | CELL-CYCLE ARREST | DASATINIB BMS-354825 | GROWTH-FACTOR RECEPTOR | COLON-CANCER CELLS | ONCOLOGY | PROSTATE-CANCER | C-SRC | Humans | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Pyrimidines - chemistry | Thiazoles - adverse effects | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Benzodioxoles - adverse effects | Benzodioxoles - chemistry | Benzodioxoles - therapeutic use | Quinazolines - chemistry | Quinolines - chemistry | src-Family Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols | Clinical Trials as Topic | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Nitriles - chemistry | Pyrimidines - adverse effects | Quinazolines - adverse effects | Thiazoles - chemistry | Quinolines - therapeutic use | Aniline Compounds - chemistry | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Nitriles - adverse effects | src-Family Kinases - chemistry | src-Family Kinases - genetics | Quinolines - adverse effects | Nitriles - therapeutic use | Cancer Biology
Journal Article
Journal Article
Neural Plasticity, ISSN 2090-5904, 2016, Volume 2016, p. 8501693
Journal Article
Biological Psychiatry, ISSN 0006-3223, 2017, Volume 82, Issue 7, pp. 488 - 499
Journal Article
British Journal of Nutrition, ISSN 0007-1145, 07/2014, Volume 112, Issue 2, pp. 203 - 213
Journal Article